×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

According to Bloomberg,  Qiagen (QGEN) approached by Thermo Fisher Scientific (TMO)

  • November 14, 2019

POTENTIAL DEAL DETAILS

StockQIAGEN N.V.SymbolQGEN
Date Announced11/13/2019Source Bloomberg
TypeNews Report
Date of Confirmation: 03/03/2020Price at Confirmation: $36.12
Potential Profit: 1.89%Annualized Profit: 6.21%

Thermo Fisher Scientific Inc. (TMO), the maker of diagnostic equipment, is considering a purchase of molecular testing firm Qiagen NV (QGEN) in what could become one of its biggest-ever acquisitions, people with knowledge of the matter said.

Updates(s):

December 11, 2019: German health technology company Siemens Healthineers is not interested in a takeover of Qiagen (QGEN), the genetic testing company which last month said it would start talks with several potential suitors.

March 03, 2020: Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and QIAGEN N.V. (QGEN), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V. (QGEN), have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.